Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug724 | COVICU Wiki | 1.00 |
| drug3851 | Syringe Wiki | 1.00 |
| drug3913 | Teduglutide Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the bioavailability of teduglutide administered as a single subcutaneous (SC) fixed dose (depending upon participant weightband assignment) delivered by a syringe injection and the same fixed dose delivered by the pen injector in healthy participants.
Description: AUC0-tlast of teduglutide will be assessed.
Measure: Area Under the Plasma Concentration Verse Time Curve From Time Zero to the Time of Last Measurable Concentration (AUC0-tlast) of Teduglutide Time: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours Post-dose of period I and period IIDescription: Cmax of teduglutide will be assessed.
Measure: Maximum Observed Plasma Concentration (Cmax) of Teduglutide Time: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours Post-dose of period I and period IIDescription: AUC0-infinity of teduglutide will be assessed.
Measure: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Teduglutide Time: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours Post-dose of period I and period IIDescription: tmax of teduglutide will be assessed.
Measure: Time of First Occurrence of Maximum Observed Plasma Concentration (Cmax) (tmax) of Teduglutide Time: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours Post-dose of period I and period IIDescription: Lambda z of teduglutide will be assessed.
Measure: Terminal Disposition Phase Rate Constant (Lambda z) of Teduglutide Time: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours Post-dose of period I and period IIDescription: t1/2 of teduglutide will be assessed.
Measure: Terminal Disposition Phase Half-Life (t1/2) of Teduglutide Time: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours Post-dose of period I and period IIDescription: CL/F for extravascular administration divided by the fraction of dose absorbed of teduglutide will be assessed.
Measure: Apparent Total Body Clearance (CL/F) of Teduglutide Time: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours Post-dose of period I and period IIDescription: Vz/F associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed of teduglutide will be assessed.
Measure: Apparent Volume of Distribution (Vz/F) of Teduglutide Time: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24 hours Post-dose of period I and period IIDescription: An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants with TEAEs will include injection site reactions and injection site injury assessments.
Measure: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Time: From start of study drug administration to follow-up (up to 18 days)Description: Vital signs will be assessed based on body temperature, respiratory rate, blood pressure, and heart rate.
Measure: Number of Participants With Clinically Significant Change in Vital Signs Time: From start of study drug administration to follow-up (up to 18 days)Description: Clinical laboratory assessments includes hematology, serum chemistry, coagulation and urinalysis. Changes in laboratory values may be considered as AE if they are judged to be clinically significant.
Measure: Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments Time: From start of study drug administration to follow-up (up to 18 days)Description: Physical examination includes examination of respiratory, cardiovascular, and gastrointestinal systems.
Measure: Number of Participants With Clinically Significant Changes in Physical Examinations Time: From start of study drug administration to follow-up (up to 18 days)Description: Number of participants with device malfunction will be assessed.
Measure: Number of Participants with Device Malfunction Time: Day 1Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports